TUESDAY, June 10, 2014 (HealthDay News) — The combination of metformin and insulin for people with type 2 diabetes may slightly increase death rates among patients, according to researchers from Vanderbilt University. Here, we examined early effects on glucose and lipid metabolism, and on certain adipose tissue and inflammatory markers during treatment for 28 days. Metformin could block the mitogenic effects of insulin, but this effect does not entirely explain the reduction in cancer incidence. If metformin alone can’t control blood sugar levels, the ACP advises combining metformin with another blood-sugar lowering medication. Relative to placebo, 16 weeks of rosiglitazone and metformin similarly reduced fasting glucose (−2.3 ± 0.5 and −2.3 ± 0.5 mmol/l) and HbA1c (−1.2 ± 0.3 and −1.6 ± 0.3%). Citation: Maruthur NM, Tseng E, Hutfless S, et al. Results: Ninety-two patients with type 2 DM (group 1, 18 females, 15 males [mean age, 62.8 ± 9.5 years]; group 2, 19 females, 11 males [mean age, 63.2 ± 8.8 years]; group 3, 16 females, 13 males [mean age, 62.0 ± 5.3 years]) and 28 age- and sex-matched healthy control subjects (18 females, 10 males; mean age, 59.1 ± 5.3 years) were enrolled.
In 2001-2002, metformin was more likely to be used in obese than non-obese patients: 13% normal weight, 33.6% overweight and 62.1% obese patients were treated with metformin. Clinical trials available indicate that the combination of the two drugs results in greater improvement in plasma glucose concentration and HbA(1c) as compared to single therapy, without increasing the occurrence of specific side effects. With regard to metformin use in patients with other comorbidities, such as hepatic dysfunction, heart failure, alcoholism, or history of lactic acidosis, responses indicate there is no consensus on when to adjust metformin therapy, but that the majority of clinicians would alter metformin therapy in varying stages or severities of these conditions. Silvio Inzucchi at Yale and another led by Dr.